Show
Sort by
-
Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?
-
Systematic review with meta-analysis : prevalence, risk factors and costs of aminosalicylate use in Crohn's disease
-
Incidence and predictors of success of adalimumab dose escalation and de-escalation in ulcerative colitis : a real-world Belgian cohort study
-
- Miscellaneous
- open access
An optimal METRIC for imaging in small bowel Crohn’s disease
-
Ursodeoxycholic acid and its taurine/glycine conjugated species reduce colitogenic dysbiosis and equally suppress experimantal colitis in mice
-
Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis
-
Tauroursodeoxycholic acid protects bile acid homeostasis under inflammatory conditions and dampens Crohn’s disease-like ileitis
-
Ursodeoxycholic acid and its taurine/glycine conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice
-
T84 monolayers are superior to Caco-2 as a model system of colonocytes
-
Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease : a practical overview